Alexion Hunts For A CEO While Investors Await Investigation Details

CEO David Hallal and CFO Vikas Sinha have both left the company amid an audit investigation, while the company said it will file a delayed 10-Q in January or earlier.

Alexion Pharmaceuticals Inc. has turned to board director and former AstraZeneca PLC CEO David Brennan to lead the company through an unexpected transition. Brennan will succeed David Hallal, effective immediately, in a leadership shakeup coinciding with an ongoing audit investigation, though the company said it was due to “personal reasons.”

The company announced the appointment Dec. 12, along with news that Chief Financial Officer Vikas Sinha has also left the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.